| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.857 | 0.003 | 0.857 | Vasodilator, coronary | 0.431 0.027 DBMET00368 | ||
| 0.854 | 0.002 | 0.854 | Calcium channel blocker | 0.646 0.003 DBMET00368 | ||
| 0.781 | 0.003 | 0.781 | Calcium channel (voltage-sensitive) blocker | 0.497 0.004 DBMET00368 | ||
| 0.75 | 0.001 | 0.75 | Calcium antagonist | 0.334 0.004 DBMET00368 | ||
| 0.74 | 0.001 | 0.74 | Calcium channel L-type blocker | 0.514 0.002 DBMET00368 | ||
| 0.735 | 0.005 | 0.735 | Vasodilator, peripheral | 0.383 0.061 DBMET00368 | ||
| 0.711 | 0.002 | 0.711 | Calcium channel L-type activator | 0.707 0.002 DBMET00368 | ||
| 0.701 | 0.001 | 0.701 | Calcium channel activator | 0.568 0.003 DBMET00368 | ||
| 0.697 | 0.004 | 0.697 | Vasodilator | 0.351 0.033 DBMET00368 | ||
| 0.556 | 0.01 | 0.556 | Cardiotonic | 0.232 0.095 DBMET00368 | ||
| 0.538 | 0.006 | 0.538 | Diuretic | 0.218 0.038 DBMET00368 | ||
| 0.537 | 0.034 | 0.537 | 15-Lipoxygenase inhibitor | 0.488 0.043 DBMET00368 | ||
| 0.486 | 0.025 | 0.486 | Spasmolytic | 0.187 0.131 DBMET00368 | ||
| 0.454 | 0.013 | 0.454 | Platelet aggregation inhibitor | |||
| 0.446 | 0.011 | 0.446 | Cyclic AMP phosphodiesterase inhibitor | 0.259 0.059 DBMET00368 | ||
| 0.453 | 0.041 | 0.568 | GABA C receptor rho-3 antagonist | 0.568 0.011 DBMET00368 | DBMET00368 | |
| 0.422 | 0.044 | 0.422 | Antithrombotic | 0.255 0.122 DBMET00368 | ||
| 0.417 | 0.046 | 0.609 | Cholesterol antagonist | 0.609 0.018 DBMET00368 | DBMET00368 | |
| 0.383 | 0.024 | 0.383 | Sigma receptor agonist | |||
| 0.417 | 0.06 | 0.417 | Transcription factor NF kappa B inhibitor | 0.341 0.08 DBMET00368 | ||
| 0.326 | 0.004 | 0.326 | Neuropeptide Y1 antagonist | 0.319 0.004 DBMET00368 | ||
| 0.39 | 0.085 | 0.473 | 5 Hydroxytryptamine release inhibitor | 0.473 0.042 DBMET00368 | DBMET00368 | |
| 0.282 | 0.007 | 0.374 | GABA C receptor rho-2 antagonist | 0.374 0.004 DBMET00368 | DBMET00368 | |
| 0.298 | 0.028 | 0.298 | Non-steroidal antiinflammatory agent | 0.275 0.034 DBMET00368 | ||
| 0.315 | 0.048 | 0.315 | Platelet antagonist | |||
| 0.271 | 0.005 | 0.271 | TRPA1 agonist | 0.107 0.076 DBMET00368 | ||
| 0.245 | 0.01 | 0.245 | Mediator release inhibitor | 0.093 0.079 DBMET00368 | ||
| 0.271 | 0.042 | 0.311 | Anesthetic general | 0.311 0.03 DBMET00368 | DBMET00368 | |
| 0.243 | 0.018 | 0.243 | Platelet activating factor antagonist | |||
| 0.226 | 0.003 | 0.226 | Potassium channel intermediate-conductance Ca-activated blocker | 0.127 0.005 DBMET00368 | ||
| 0.269 | 0.052 | 0.269 | Psychostimulant | |||
| 0.217 | 0.017 | 0.217 | Farnesoid X receptor antagonist | |||
| 0.199 | 0.005 | 0.282 | Glutamate release inhibitor | 0.282 0.004 DBMET00368 | DBMET00368 | |
| 0.174 | 0.004 | 0.174 | Mineralocorticoid receptor antagonist | |||
| 0.174 | 0.004 | 0.174 | Aldosterone antagonist | |||
| 0.176 | 0.01 | 0.176 | Adenosine A3 receptor antagonist | 0.095 0.029 DBMET00368 | ||
| 0.208 | 0.059 | 0.208 | P-glycoprotein inhibitor | 0.148 0.12 DBMET00368 | ||
| 0.249 | 0.101 | 0.249 | Hypoxia-inducible factor 1 alpha inhibitor | 0.241 0.109 DBMET00368 | ||
| 0.18 | 0.036 | 0.18 | CF transmembrane conductance regulator agonist | |||
| 0.162 | 0.026 | 0.162 | Ca(v)2.2 blocker | 0.076 0.069 DBMET00368 | ||
| 0.214 | 0.08 | 0.214 | RNA-directed DNA polymerase inhibitor | 0.206 0.09 DBMET00368 | ||
| 0.207 | 0.078 | 0.207 | Anticonvulsant | |||
| 0.138 | 0.01 | 0.138 | Bile acid receptor antagonist | |||
| 0.295 | 0.168 | 0.327 | DNA polymerase beta inhibitor | 0.327 0.151 DBMET00368 | DBMET00368 | |
| 0.145 | 0.024 | 0.145 | Androgen antagonist | |||
| 0.144 | 0.029 | 0.144 | Adenylate kinase inhibitor | |||
| 0.185 | 0.075 | 0.185 | Hepatoprotectant | |||
| 0.169 | 0.06 | 0.169 | Phospholipase A2 inhibitor | 0.123 0.113 DBMET00368 | ||
| 0.113 | 0.007 | 0.113 | Glutamate (mGluR6) antagonist | 0.104 0.009 DBMET00368 | ||
| 0.171 | 0.069 | 0.179 | ATPase inhibitor | 0.179 0.059 DBMET00368 | DBMET00368 | |
| 0.275 | 0.176 | 0.304 | DNA directed DNA polymerase inhibitor | 0.304 0.159 DBMET00368 | DBMET00368 | |
| 0.11 | 0.013 | 0.11 | Calcium channel T-type blocker | |||
| 0.149 | 0.054 | 0.149 | Pregnane X receptor agonist | |||
| 0.247 | 0.152 | 0.247 | Calpain 2 inhibitor | |||
| 0.114 | 0.021 | 0.114 | Glycine receptor antagonist | |||
| 0.134 | 0.041 | 0.134 | Alpha 2c adrenoreceptor antagonist | |||
| 0.098 | 0.007 | 0.098 | Thromboxane synthase inhibitor | 0.072 0.016 DBMET00368 | ||
| 0.112 | 0.022 | 0.129 | Granulocyte macrophage colony stimulating factor agonist | 0.129 0.011 DBMET00368 | DBMET00368 | |
| 0.17 | 0.08 | 0.17 | Lipocortins synthesis antagonist | |||
| 0.145 | 0.06 | 0.145 | Heat shock protein 70 antagonist | 0.14 0.076 DBMET00368 | ||
| 0.122 | 0.038 | 0.169 | GABA C receptor rho-1 antagonist | 0.169 0.015 DBMET00368 | DBMET00368 | |
| 0.132 | 0.049 | 0.132 | Alpha 2b adrenoreceptor antagonist | |||
| 0.098 | 0.017 | 0.098 | Beta adrenoreceptor antagonist | |||
| 0.127 | 0.046 | 0.141 | GABA C receptor antagonist | 0.141 0.035 DBMET00368 | DBMET00368 | |
| 0.146 | 0.068 | 0.196 | Mannose-6-phosphate isomerase inhibitor | 0.196 0.033 DBMET00368 | DBMET00368 | |
| 0.165 | 0.087 | 0.183 | Succinate dehydrogenase inhibitor | 0.183 0.064 DBMET00368 | DBMET00368 | |
| 0.237 | 0.163 | 0.242 | Beta lactamase inhibitor | 0.242 0.16 DBMET00368 | DBMET00368 | |
| 0.112 | 0.039 | 0.112 | Alpha 1 adrenoreceptor antagonist | |||
| 0.106 | 0.033 | 0.106 | Alpha 1b adrenoreceptor antagonist | |||
| 0.117 | 0.046 | 0.117 | Antiadrenergic | |||
| 0.085 | 0.015 | 0.085 | Phosphorylase inhibitor | |||
| 0.114 | 0.046 | 0.114 | Adrenaline antagonist | |||
| 0.102 | 0.035 | 0.102 | Alpha 1a adrenoreceptor antagonist | |||
| 0.081 | 0.017 | 0.081 | Beta 1 adrenoreceptor antagonist | |||
| 0.09 | 0.026 | 0.09 | Alpha 1d adrenoreceptor antagonist | |||
| 0.082 | 0.019 | 0.082 | Thromboxane antagonist | |||
| 0.086 | 0.023 | 0.086 | Potassium channel (Tandem pore domain) blocker | |||
| 0.113 | 0.051 | 0.117 | Toll-Like receptor 4 antagonist | 0.117 0.046 DBMET00368 | DBMET00368 | |
| 0.196 | 0.135 | 0.196 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.15 | 0.089 | 0.151 | Arachidonic acid antagonist | 0.151 0.088 DBMET00368 | DBMET00368 | |
| 0.248 | 0.188 | 0.354 | Alpha-glucosidase inhibitor | 0.354 0.134 DBMET00368 | DBMET00368 | |
| 0.098 | 0.038 | 0.098 | Alpha 2a adrenoreceptor antagonist | |||
| 0.1 | 0.041 | 0.1 | Neuropeptide Y antagonist | |||
| 0.075 | 0.018 | 0.075 | Thromboxane A2 antagonist | |||
| 0.246 | 0.189 | 0.251 | Transcription factor inhibitor | 0.251 0.186 DBMET00368 | DBMET00368 | |
| 0.113 | 0.057 | 0.113 | Interleukin 2 antagonist | 0.112 0.059 DBMET00368 | ||
| 0.108 | 0.052 | 0.108 | Alpha adrenoreceptor antagonist | |||
| 0.091 | 0.036 | 0.091 | Transforming growth factor beta 3 antagonist | |||
| 0.143 | 0.088 | 0.143 | Interferon gamma antagonist | 0.14 0.092 DBMET00368 | ||
| 0.118 | 0.065 | 0.128 | Calcium channel N-type blocker | 0.128 0.054 DBMET00368 | DBMET00368 | |
| 0.115 | 0.064 | 0.121 | Photosensitizer | 0.121 0.056 DBMET00368 | DBMET00368 | |
| 0.071 | 0.02 | 0.071 | Dopamine transporter inhibitor | 0.043 0.04 DBMET00368 | ||
| 0.053 | 0.006 | 0.053 | Transforming growth factor beta 2 antagonist | |||
| 0.069 | 0.022 | 0.129 | Dihydroorotate dehydrogenase inhibitor | 0.129 0.006 DBMET00368 | DBMET00368 | |
| 0.066 | 0.02 | 0.066 | Nicotinic alpha3beta2 receptor antagonist | 0.052 0.04 DBMET00368 | ||
| 0.134 | 0.091 | 0.148 | NOS3 expression enhancer | 0.148 0.074 DBMET00368 | DBMET00368 | |
| 0.12 | 0.077 | 0.126 | Cyclooxygenase 3 inhibitor | 0.126 0.071 DBMET00368 | DBMET00368 | |
| 0.099 | 0.061 | 0.099 | Sphingomyelinase inhibitor | |||
| 0.068 | 0.032 | 0.068 | Dopamine uptake inhibitor | |||
| 0.057 | 0.024 | 0.057 | Potassium channel (Inward rectifier) activator | |||
| 0.054 | 0.023 | 0.054 | Potassium channel (ATP-sensitive) activator | |||
| 0.099 | 0.069 | 0.113 | Carbonic anhydrase XV inhibitor | 0.113 0.052 DBMET00368 | DBMET00368 | |
| 0.072 | 0.042 | 0.072 | Phosphodiesterase III inhibitor | |||
| 0.059 | 0.032 | 0.06 | Pregnane X receptor antagonist | 0.06 0.031 DBMET00368 | DBMET00368 | |
| 0.133 | 0.106 | 0.133 | Ca2+-transporting ATPase inhibitor | 0.132 0.11 DBMET00368 | ||
| 0.045 | 0.019 | 0.045 | Phenylethanolamine N methyltransferase inhibitor | 0.041 0.027 DBMET00368 | ||
| 0.106 | 0.08 | 0.106 | Microtubule formation inhibitor | |||
| 0.062 | 0.038 | 0.062 | Potassium channel (Ca-activated) blocker | |||
| 0.06 | 0.036 | 0.06 | Potassium channel Kv1.5 blocker | |||
| 0.087 | 0.065 | 0.087 | Potassium channel activator | |||
| 0.089 | 0.068 | 0.089 | ABCA1 expression enhancer | |||
| 0.096 | 0.076 | 0.096 | Beta glucuronidase inhibitor | |||
| 0.082 | 0.063 | 0.082 | Alpha 2 adrenoreceptor antagonist | |||
| 0.047 | 0.028 | 0.055 | Dihydroorotase inhibitor | 0.055 0.02 DBMET00368 | DBMET00368 | |
| 0.042 | 0.027 | 0.042 | Glutamate (mGluR1a) antagonist | |||
| 0.058 | 0.048 | 0.058 | NMDA receptor glycine site agonist | |||
| 0.13 | 0.12 | 0.144 | LIM domain kinase 1 inhibitor | 0.144 0.104 DBMET00368 | DBMET00368 | |
| 0.194 | 0.187 | 0.194 | Apoptosis antagonist | |||
| 0.023 | 0.019 | 0.023 | NMDA receptor glycine site antagonist | |||
| 0.054 | 0.052 | 0.054 | Adrenaline uptake inhibitor | |||
| 0.08 | 0.078 | 0.08 | Bromodomain-containing protein 2 inhibitor | |||
| 0.092 | 0.091 | 0.31 | Anesthetic local | 0.31 0.012 DBMET00368 | DBMET00368 | |
| 0.039 | 0.038 | 0.055 | GABA B receptor antagonist | 0.055 0.015 DBMET00368 | DBMET00368 | |
| 0.128 | 0.129 | 0.159 | Amyloid beta precursor protein antagonist | 0.159 0.092 DBMET00368 | DBMET00368 | |
| 0.105 | 0.106 | 0.107 | Sphingosine 1-phosphate receptor 4 antagonist | 0.107 0.1 DBMET00368 | DBMET00368 | |
| 0.109 | 0.114 | 0.138 | Cytidine deaminase inhibitor | 0.138 0.085 DBMET00368 | DBMET00368 | |
| 0.062 | 0.068 | 0.069 | MDM2 inhibitor | 0.069 0.042 DBMET00368 | DBMET00368 | |
| 0.035 | 0.042 | 0.042 | Integrin alpha1beta1 antagonist | 0.042 0.016 DBMET00368 | DBMET00368 | |
| 0.169 | 0.178 | 0.269 | Lipoxygenase inhibitor | 0.269 0.088 DBMET00368 | DBMET00368 | |
| 0.172 | 0.183 | 0.311 | Thyroid hormone beta antagonist | 0.311 0.082 DBMET00368 | DBMET00368 | |
| 0.052 | 0.064 | 0.069 | Transcription factor AP-1 inhibitor | 0.069 0.032 DBMET00368 | DBMET00368 | |
| 0.17 | 0.19 | 0.312 | Thyroid hormone antagonist | 0.312 0.088 DBMET00368 | DBMET00368 | |
| 0.233 | 0.256 | 0.319 | MAP kinase 1 inhibitor | 0.319 0.161 DBMET00368 | DBMET00368 | |
| 0.085 | 0.11 | 0.164 | Cholesterol synthesis inhibitor | 0.164 0.038 DBMET00368 | DBMET00368 | |
| 0.071 | 0.1 | 0.093 | Interleukin 5 antagonist | 0.093 0.051 DBMET00368 | DBMET00368 | |
| 0.055 | 0.085 | 0.082 | Calcium channel P-type blocker | 0.082 0.013 DBMET00368 | DBMET00368 | |
| 0.037 | 0.068 | 0.058 | Benzodiazepine antagonist | 0.058 0.015 DBMET00368 | DBMET00368 | |
| 0.028 | 0.062 | 0.05 | Angiotensin AT1 receptor antagonist | 0.05 0.017 DBMET00368 | DBMET00368 | |
| 0.123 | 0.159 | 0.284 | Aryl hydrocarbon receptor agonist | 0.284 0.066 DBMET00368 | DBMET00368 | |
| 0.088 | 0.13 | 0.108 | Toll-Like receptor 2 antagonist | 0.108 0.093 DBMET00368 | DBMET00368 | |
| 0.046 | 0.089 | 0.076 | Prostaglandin-E synthase inhibitor | 0.076 0.042 DBMET00368 | DBMET00368 | |
| 0.182 | 0.226 | 0.273 | Histamine release inhibitor | 0.273 0.139 DBMET00368 | DBMET00368 | |
| 0.012 | 0.056 | 0.025 | Kynurenine 3 monooxygenase inhibitor | 0.025 0.02 DBMET00368 | DBMET00368 | |
| 0.153 | 0.204 | 0.248 | 12-Lipoxygenase inhibitor | 0.248 0.11 DBMET00368 | DBMET00368 | |
| 0.021 | 0.073 | 0.037 | Angiotensin II receptor antagonist | 0.037 0.019 DBMET00368 | DBMET00368 | |
| 0.056 | 0.11 | 0.094 | Potassium channel (Ca-activated) activator | 0.094 0.06 DBMET00368 | DBMET00368 | |
| 0.032 | 0.086 | 0.077 | GABA A receptor antagonist | 0.077 0.023 DBMET00368 | DBMET00368 | |
| 0.031 | 0.087 | 0.06 | Diacylglycerol O-acyltransferase inhibitor | 0.06 0.026 DBMET00368 | DBMET00368 | |
| 0.047 | 0.104 | 0.064 | Interferon inducer | 0.064 0.044 DBMET00368 | DBMET00368 | |
| 0.09 | 0.148 | 0.152 | Sphingosine 1-phosphate receptor 2 agonist | 0.152 0.025 DBMET00368 | DBMET00368 | |
| 0.031 | 0.093 | 0.071 | GABA receptor antagonist | 0.071 0.025 DBMET00368 | DBMET00368 | |
| 0.139 | 0.212 | 0.196 | Prostaglandin dehydrogenase inhibitor | 0.196 0.159 DBMET00368 | DBMET00368 | |
| 0.04 | 0.116 | 0.071 | Benzodiazepine agonist | 0.071 0.049 DBMET00368 | DBMET00368 | |
| 0.127 | 0.204 | 0.174 | Streptokinase A inhibitor | 0.174 0.151 DBMET00368 | DBMET00368 | |
| 0.048 | 0.135 | 0.074 | Interferon agonist | 0.074 0.062 DBMET00368 | DBMET00368 | |
| 0.069 | 0.159 | 0.119 | Bone formation stimulant | 0.119 0.086 DBMET00368 | DBMET00368 | |
| 0.085 | 0.178 | 0.124 | Protein-tyrosine phosphatase inhibitor | 0.124 0.109 DBMET00368 | DBMET00368 | |
| 0.013 | 0.107 | 0.036 | Cholesterol ester transfer protein antagonist | 0.036 0.016 DBMET00368 | DBMET00368 | |
| 0.074 | 0.168 | 0.115 | Alkaline phosphatase inhibitor | 0.115 0.093 DBMET00368 | DBMET00368 | |
| 0.061 | 0.155 | 0.133 | GABA receptor agonist | 0.133 0.046 DBMET00368 | DBMET00368 | |
| 0.011 | 0.115 | 0.04 | Glutamate (mGluR2) antagonist | 0.04 0.012 DBMET00368 | DBMET00368 | |
| 0.066 | 0.171 | 0.137 | Nav1.6 sodium channel blocker | 0.137 0.07 DBMET00368 | DBMET00368 | |
| 0.047 | 0.16 | 0.086 | GABA A receptor agonist | 0.086 0.054 DBMET00368 | DBMET00368 | |
| 0.096 | 0.216 | 0.166 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.166 0.125 DBMET00368 | DBMET00368 | |
| 0.014 | 0.135 | 0.05 | Glutamate (mGluR group II) antagonist | 0.05 0.016 DBMET00368 | DBMET00368 | |
| 0.031 | 0.154 | 0.065 | Nav1.8 sodium channel blocker | 0.065 0.064 DBMET00368 | DBMET00368 | |
| 0.075 | 0.218 | 0.142 | Dual specificity phosphatase 3 inhibitor | 0.142 0.104 DBMET00368 | DBMET00368 | |
| 0.071 | 0.261 | 0.144 | Insulin sensitizer | 0.144 0.142 DBMET00368 | DBMET00368 | |
| 0.091 | 0.309 | 0.213 | Hypoglycemic | 0.213 0.101 DBMET00368 | DBMET00368 | |
| 0.025 | 0.267 | 0.103 | Glutamate (mGluR) antagonist | 0.103 0.033 DBMET00368 | DBMET00368 | |
| 0.157 | 0.4 | 0.274 | Caspase 9 stimulant | 0.274 0.223 DBMET00368 | DBMET00368 | |
| 0.03 | 0.285 | 0.148 | Glutamate receptor antagonist | 0.148 0.053 DBMET00368 | DBMET00368 | |
| 0.024 | 0.291 | 0.112 | 5-Lipoxygenase inhibitor | 0.112 0.055 DBMET00368 | DBMET00368 | |
| 0.045 | 0.316 | 0.112 | Toll-Like receptor antagonist | 0.112 0.098 DBMET00368 | DBMET00368 | |
| 0.035 | 0.307 | 0.091 | Breast cancer-resistant protein inhibitor | 0.091 0.064 DBMET00368 | DBMET00368 | |
| 0.063 | 0.381 | 0.205 | DNA damaging | 0.205 0.111 DBMET00368 | DBMET00368 | |
| 0.045 | 0.37 | 0.23 | Hypolipemic | 0.23 0.077 DBMET00368 | DBMET00368 | |
| 0.025 | 0.411 | 0.074 | Viral attachment inhibitor | 0.074 0.064 DBMET00368 | DBMET00368 | |
| 0.032 | 0.522 | 0.149 | Insulin secretagoues | 0.149 0.076 DBMET00368 | DBMET00368 | |
| 0.041 | 0.672 | 0.282 | Cyclophilin D inhibitor | 0.282 0.179 DBMET00368 | DBMET00368 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |